Biotechnology Animations – Biotechnology Illustrations

Intra-Cellular Therapies Announces The Successful Completion Of A Phase Ib/II Study Of ITI-007 In Patients With Schizophrenia
Intra-Cellular Therapies, Inc. announced the results from a Phase Ib/II clinical trial in patients with schizophrenia with ITI-007, the Company's unique, investigational new drug for the treatment of schizophrenia. The trial met its primary endpoint demonstrating that ITI-007 was safe and well-tolerated in patients with stabilized schizophrenia...

ANA598 Demonstrates SVR12 In 100% Of First Group Of HCV Patients Randomized To Stop All Treatment At Week 24
Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS) announced that six of six patients (100%) in the ANA598 200 mg twice daily (bid) arm who were randomized to stop all treatment at Week 24 in an ongoing Phase II trial maintained undetectable levels of virus 12 weeks after stopping treatment, referred to as Sustained Virological Response 12, or SVR12...

Bionovo To Advance Menerba To Phase 3 Clinical Testing In Europe
Bionovo, Inc. (Nasdaq: BNVI) announced that it has received final guidance from the European Medicines Agency (EMA) in order to advance Menerba, the company's lead drug candidate for menopausal symptoms, to Phase 3 clinical trials in Europe. The guidance defines the clinical and regulatory pathway to a European marketing authorization for Menerba...

ArQule Announces Initiation By Kyowa Hakko Kirin Of Phase 2 Clinical Trial In Asia With ARQ 197 In Gastric Cancer
ArQule, Inc. (Nasdaq: ARQL) announced the initiation of a Phase 2, single agent trial with ARQ 197 in gastric cancer by Kyowa Hakko Kirin, its exclusive licensee for the development and commercialization of ARQ 197 in the Asian territory consisting of Japan, China (including Hong Kong), South Korea and Taiwan...

ACT Files Documentation With FDA For Clinical Trials Using ES Cells To Treat Eye Disease
Advanced Cell Technology, Inc...

Etubics Enters Phase I Cancer Clinical Trials Focused On Colorectal Cancer
Etubics Corporation, a biopharmaceutical company developing "next generation" vector vaccines, has entered into Phase I trials at Duke University with its ETBX-011, a therapeutic vaccine candidate that is intended to treat Carcinoembryonic Antigen (CEA)-expressing cancers such as colorectal cancer. Etubics dosed its first patient yesterday. Etubics was recently granted clearance by the U.S...

Advaxis Phase I Survival Update
Advaxis, Inc., (OTCBB: ADXS), the live, attenuated Listeria monocytogenes (Lm) immunotherapy company, has updated the survival information from its phase 1 trial of ADXS11-001 which assessed the safety of this agent in advanced, metastatic, progressive cervix cancer in women whose disease progressed subsequent to treatment with cytotoxic therapy...

New England Journal Of Medicine Publishes Data From Pivotal Phase 3 PROVENGE IMPACT Study
Dendreon Corporation (Nasdaq: DNDN) announced the publication of data from the pivotal Phase 3 IMPACT study in the New England Journal of Medicine, showing that PROVENGE® (sipuleucel-T) demonstrated a statistically significant improvement in overall survival compared to control in men with asymptomatic or minimally symptomatic metastatic castration resistant prostate cancer (mCRPC)...

Teva Respiratory Announces Positive Results From Phase III Trial Of BDP HFA Nasal Aerosol In Seasonal Allergic Rhinitis
Teva Respiratory announced positive results from a Phase III trial evaluating the efficacy and safety of beclomethasone dipropionate (BDP) hydrofluoroalkane (HFA) Nasal Aerosol in the treatment of seasonal allergic rhinitis (SAR). The study met all efficacy endpoints, demonstrating a statistically significant benefit as compared to placebo...

Pharmasset Initiates Phase 1b Multiple Ascending Dose Clinical Trial Of PSI-938 In Patients With Chronic Hepatitis C
Pharmasset, Inc. (Nasdaq: VRUS) announced that safety and pharmacokinetic data from the PSI-352938 ("PSI-938") single ascending dose study support progression to a multiple ascending dose trial with PSI-938, which has initiated dosing. PSI-938 is a guanine nucleotide analog polymerase inhibitor for the treatment of chronic hepatitis C virus (HCV) infection...

Angiotech Pharmaceuticals And Partner Athersys Announce Positive Results From Phase I Study Of MultiStem(R) In Heart Attack Patients
Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP) ("Angiotech") and partner Athersys, Inc. (NASDAQ: ATHX) announced positive results from its phase I clinical trial of MultiStem(R), its allogeneic cell therapy product, administered to individuals following acute myocardial infarction (AMI), more commonly referred to as a heart attack...

Curemark Opens Autism Trials At New Jersey Site
Curemark, LLC, a drug research and development company focused on the treatment of neurological diseases, announced that Saint Peter's University Hospital in New Brunswick, New Jersey, is participating in the company's Phase III clinical trials for CM-AT, Curemark's autism treatment. Saint Peter's is affiliated with the Drexel University College of Medicine in Philadelphia...

Global Breakthrough In Treatment Of Dementia 'Within Reach' - Clinical Trial In Scotland Recruiting
A Glasgow-based medical research company is leading a worldwide sleep study which could radically reduce the symptoms associated with dementia. The groundbreaking trial, conducted by CPS Research, is the first of its kind to investigate the use of sleep hormone melatonin as an add on treatment for dementia. The study is already showing remarkable initial results in volunteers from Scotland...

Hospira Begins Phase I U.S. Clinical Trial Of Biosimilar Erythropoietin In Renal Patients
Hospira, Inc. (NYSE: HSP), the world leader in generic injectable pharmaceuticals, announced the start of a U.S. Phase I clinical trial of its biosimilar erythropoietin (EPO) in patients with renal (kidney) dysfunction who have anemia, an important step on the road toward introducing a biosimilar product in the United States...

NYU Langone Begins Clinical Trial Offering Vascular-Targeted Photodynamic Therapy To Patients With Localized Prostate Cancer
NYU Langone Medical Center has begun a clinical trial offering vascular-targeted photodynamic therapy to patients with localized prostate cancer. This novel, minimally invasive procedure uses a light-activated drug to deliver light energy waves by way of laser fibers in order to destroy prostate cancer cells...